美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

231.99

-11.1000-4.57%

盘后：231.21-0.7800-0.34%19:59 EDT

成交量：29.56万

成交额：7,010.13万

市值：6.20亿

市盈率：- -

高：244.67

开：241.52

低：230.22

收：243.09

52周最高：341.93

52周最低：102.35

股本：267.45万

流通股本：267.45万

量比：0.45

换手率：11.05%

股息：0.90

股息率：0.39%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

美国食品药品监督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用于治疗伴有ESR1突变的晚期乳腺癌。

医疗健康板块动态：市场快讯汇总

丹阳家长注意！2027年度学生医保缴费启动

一项针对雇主的调查预计，美国医疗保健成本将出现20多年来最大涨幅：2027年雇主提供的医疗保险成本预计将较今年上升8.2

医疗板块市场快讯：和黄医药与GSK达成许可协议，AstraZeneca新药前景获看好

医疗保健板块市场快讯：比特币涨势带动加密市场乐观情绪，阿斯利康新药潜力引关注

医疗健康板块市场综述：行业动态与个股追踪

美国卫生与公众服务部医疗保险和医疗补助服务中心：特朗普政府宣布拨款1.2亿美元，用于扩大印第安纳州母婴健康服务，提高初级

中国生物制药(01177.HK)：TQB6426“GPC3 ADC”临床试验申请获FDA批准

中国生物制药：附属公司正大天晴自主研发的国家1类新药TQB6426临床试验申请获FDA批准

American Healthcare REIT（AHR）宣布完成收购八个高端养老社区涉资近7亿美元

医疗保健板块综述：市场快讯

中国生物制药早盘涨超4% TQB6426获FDA批准开展临床

这些女性在休产假期间被解雇。是的，这合法，而且可能比你想象的更常见

环球市场播报

医疗保健板块市场快讯汇总

联合治疗（UTHR）雾化吸入剂Tyvaso扩大适应症申请获FDA受理

翰宇药业(300199.SZ)：坪山分公司通过美国FDA现场检查

翰宇药业：坪山分公司第二次通过FDA现场检查

医疗保健板块动态：市场快讯汇总

美股异动 | 礼来(LLY.US)涨1.69% 阿尔茨海默病血液检测获FDA批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LABU/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":231.99,"timestamp":1791835200000,"preClose":243.09,"halted":0,"volume":295561,"hourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"delay":0,"changeRate":-0.04566210045662098,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"未开盘","change":-11.1,"latestTime":"10-12 16:00:00 EDT","open":241.52,"high":244.6716,"low":230.2215,"amount":70101341.22782,"amplitude":0.059443,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":243.09,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.003877,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":242.43,"preClose":243.09,"latestTime":"09:29 EDT","volume":24862,"amount":6085203.2304,"timestamp":1791811795117,"change":-0.66,"changeRate":-0.002715,"amplitude":0.021844},"postHourTrading":{"tag":"盘后","latestPrice":231.21,"preClose":231.99,"latestTime":"19:59 EDT","volume":3834,"amount":888365.3656,"timestamp":1791849594803,"change":-0.78,"changeRate":-0.003362,"amplitude":0.007343},"volumeRatio":0.453297,"impliedVol":0.9772,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.453297,"shares":2674486,"dividePrice":0.8994,"high":244.6716,"amplitude":0.059443,"preClose":243.09,"low":230.2215,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":231.99,"eps":0,"divideRate":0.003877,"volume":295561,"delay":0,"ttmEps":0,"open":241.52,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.38,"twentyDayClose":268.39,"sixtyDayClose":265.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665935968","title":"美国食品药品监督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用于治疗伴有ESR1突变的晚期乳腺癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935968","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935968?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 03:47","pubTimestamp":1788551256,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2462157665.USD","LU2468319806.SGD","BK4007","IE00B3T34201.USD","LU2237443978.SGD","LU0128525929.USD","LU2417539215.USD","LU0889565916.HKD","LU1267930573.SGD","LU2237443465.HKD","AZNH","LU2456880835.USD","BK4588","LU2237443382.USD","LU0320765992.SGD","LU0058720904.USD","LU1829250122.USD","LU0310800379.SGD","BK4568","LU0109394709.USD","AZN","LABU","LU0708994859.HKD","LU2237443622.USD","159151","LU0432979614.USD","LU2237443895.HKD","LU2237443549.SGD","LU0289739699.SGD","LU2236285917.USD","BK4585","LU2089984988.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136673456","title":"医疗健康板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1136673456","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136673456?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 00:24","pubTimestamp":1788539073,"startTime":"0","endTime":"0","summary":"最新一期聚焦医疗健康领域的市场快讯已经发布，仅在道琼斯通讯社平台独家呈现，更新时段分别为美东时间凌晨4:20、中午12:20及下午4:50。分析师们认为，此项交易、上半年销售势头以及中国监管机构另行批准的进展，或将显著提升市场对和黄医药业绩指引的可见度。该公司预计2026年肿瘤学与免疫学领域收入将在3.3亿至4.5亿美元之间。目前该公司股价报22.60港元，涨幅为3.3%。以太坊上涨4.7%至2,506美元，瑞波币攀升7.4%至1.45美元，Solana则上涨4.8%至104.45美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XBI","XLV","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334816","title":"丹阳家长注意！2027年度学生医保缴费启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334816","media":"丹阳发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334816?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 20:05","pubTimestamp":1788523500,"startTime":"0","endTime":"0","summary":"为充分保障在校学生的医疗保险待遇，丹阳市2027年度学生参加城乡居民医疗保险的参保登记工作由学校统一为学生办理，个人缴费标准为450元，长期护理保险根据国家规定暂不单独筹资。被认定为资助参保救助对象的学生，可以选择参加认定地基本医疗保险，丹阳市救助学生个人缴费部分由社会医疗救助基金承担，个人无需缴费。同一年度第二次住院，起付标准按相应医疗机构级别标准降低50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-04/doc-iniqskun4096571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XLV","BK4585","LABU","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380422","title":"一项针对雇主的调查预计，美国医疗保健成本将出现20多年来最大涨幅：2027年雇主提供的医疗保险成本预计将较今年上升8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664380422?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 16:43","pubTimestamp":1788511437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","XBI","XLV","BK4585","BK4581","MHIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161674237","title":"医疗板块市场快讯：和黄医药与GSK达成许可协议，AstraZeneca新药前景获看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1161674237","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161674237?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 16:22","pubTimestamp":1788510155,"startTime":"0","endTime":"0","summary":"花旗分析师在报告中指出，和黄医药与葛兰素史克达成的合作协议，实际上是对这家总部位于香港的生物制药公司某一特定候选药物平台的价值背书——尽管该药物尚未进入临床试验阶段。此番和黄医药与GSK签署的授权协议，在剔除净销售额特许权使用费后，潜在交易总额最高可达12.95亿美元，标的为一种癌症治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4588","XLV","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154879404","title":"医疗保健板块市场快讯：比特币涨势带动加密市场乐观情绪，阿斯利康新药潜力引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1154879404","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154879404?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 04:58","pubTimestamp":1788469126,"startTime":"0","endTime":"0","summary":"最新一期的医疗保健板块市场快讯已发布，涵盖多家重要企业的动态与分析师观点。比特币自8月以来的上涨走势，为加密货币市场注入了乐观情绪。\"目前，比特币已突破8万美元大关，最新报81,054美元，涨幅达4.7%。\"阿斯利康股价上涨1.5%。在英国市场，一项重大新合同的整合延迟以及劳动力成本正在拖累业绩表现。\"Jefferies维持对Sonic的持有评级，目标价定为每股21.00澳元，该股周三收于18.73澳元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","XBI","XLV","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188599563","title":"医疗健康板块市场综述：行业动态与个股追踪","url":"https://stock-news.laohu8.com/highlight/detail?id=1188599563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188599563?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 00:22","pubTimestamp":1788452559,"startTime":"0","endTime":"0","summary":"0810 GMT——Berenberg分析师在研究报告中指出，阿斯利康治疗慢性阻塞性肺病的新药若能在所有患者群体中展现出有效性，有望成为该领域的市场领军者。这家英国药企今年早些时候公布的初期试验结果显示，托佐利单抗在既往吸烟者的主要人群及整体人群中均带来了获益，且在不同肺功能阶段皆展现疗效。Berenberg表示：“我们认为减少30%的急性加重将是一个极为积极的结果，且超出预期。”该公司股价上涨1.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","LABU","XBI","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877326","title":"美国卫生与公众服务部医疗保险和医疗补助服务中心：特朗普政府宣布拨款1.2亿美元，用于扩大印第安纳州母婴健康服务，提高初级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877326?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 21:22","pubTimestamp":1788441723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1983260115.SGD","BK4566","LU1093756168.USD","BK4154","LU1093756325.SGD","LU0256863811.USD","LU0070302665.USD","IHF","BK4581","BK4533","SG9999014021.USD","HUM","LU0417517546.SGD","XLV","FXH","XBI","SG9999014005.SGD","BK4588","LU0238689110.USD","LU0266013472.USD","LABU","LU0320765489.SGD","LU0208291251.USD","RSPH","LU0170899867.USD","BK4585","SG9999014013.SGD","LU0390134368.USD","LU0211331839.USD","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872828","title":"中国生物制药(01177.HK)：TQB6426“GPC3 ADC”临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872828?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 20:42","pubTimestamp":1788439353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","IBBJ","BMED","BK4585","PSYK","MDTX","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874071","title":"中国生物制药：附属公司正大天晴自主研发的国家1类新药TQB6426临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874071?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 20:41","pubTimestamp":1788439284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PSYK","MDTX","BK4585","BMED","IBBJ","LABU","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664791008","title":"American Healthcare REIT（AHR）宣布完成收购八个高端养老社区 涉资近7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664791008","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664791008?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 19:17","pubTimestamp":1788434240,"startTime":"0","endTime":"0","summary":"金吾财讯 | American Healthcare REIT 宣布以约6.96亿美元的总价收购了八个A级高端老年住宅社区，一举打入供应受限的美国东北部养老地产核心市场。据悉，AHR在完成交易后，将另外两项非核心社区的购买协议以成本价转让给了另一家机构投资者。而随着本次收购落地，AHR在2026年年内完成的总投资额已突破20亿美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/Nzg4NjU0MjU3NDIxMDY0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzg4NjU0MjU3NDIxMDY0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GLS.SI","XBI","BK6142","DFRA","RNTY","PSCF","JJJ.SI","BK4581","MDIV","BK4585","BK4225","AHR","XLV","SRT.SI","YLDW","IVRA","SRU.SI","RJMG","BPRE","CLR.SI","IQRA","LABU","8C8U.SI","CFA.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195881897","title":"医疗保健板块综述：市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1195881897","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195881897?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:23","pubTimestamp":1788423797,"startTime":"0","endTime":"0","summary":"澳大利亚国家老年人护理分类起步价上调2.55%，这一幅度远低于Regis Healthcare及其他住宅式老年护理服务商所面临的成本通胀压力。瑞银分析指出，2026财年医疗行业工资通胀率已达3.8%。\"该机构将Regis的目标股价从每股6.75澳元下调至5.95澳元，但维持中性评级。该股目前下跌27%，报4.31澳元。诺华股价下跌0.75%，罗氏股价上涨0.8%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","BK4588","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238088","title":"中国生物制药早盘涨超4% TQB6426获FDA批准开展临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238088","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664238088?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 10:28","pubTimestamp":1788402480,"startTime":"0","endTime":"0","summary":"模拟交易客户端中国生物制药早盘涨近5%。截至发稿，股价上涨4.47%，现报5.50港元，成交额1.54亿港元。中国生物制药旗下正大天晴自主研发的创新型GPC3抗体药物偶联物TQB6426，于近日获得美国食品药品监督管理局临床试验默认许可，拟用于晚期恶性肿瘤治疗。至此，TQB6426拿下中美两大核心医药市场临床准入资质，成为公司创新药全球化开发的重要里程碑。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-03/doc-iniqpeka1141170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YT58.USD","BK1589","BK1521","BK1515","BK4588","BK4585","BK1191","LABU","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843670","title":"这些女性在休产假期间被解雇。是的，这合法，而且可能比你想象的更常见","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843670","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843670?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 00:57","pubTimestamp":1788368220,"startTime":"0","endTime":"0","summary":"妇女与家庭伙伴关系的高级研究员凯瑟琳·加拉格尔·罗宾斯表示，很难说女性在产假期间被解雇有多普遍，但一些指标表明这是一个持续存在的问题。近期数据显示，女性承担了失业的主要冲击。对于处于离职生育和照顾新生儿这一脆弱地位的女性来说，在此期间失业的可能性感觉像一个永远笼罩的威胁。美国确实存在法律保护工人免受因休产假或与怀孕或照顾新生儿相关的其他便利安排而受到歧视。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-03/doc-iniqnieq7440478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["DEI","BK4194","BK4588","LABU","BK4585","BK4223","BK4581","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190612977","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1190612977","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190612977?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 00:26","pubTimestamp":1788366410,"startTime":"0","endTime":"0","summary":"该分析师在研究报告中写道，公司对盈利能力的展望比市场预期更为乐观。Equita SIM维持对该股的买入评级。截至发稿，股价报157.95欧元，下跌1%。2208 ET - CIMB证券分析师Chun Sung Oong在报告中表示，德里高等法院任命法务审计师追查与前Fortis发起人Malvinder Singh和Shivinder Singh相关的涉嫌资产转移事件，对IHH医疗的直接影响可能微乎其微。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU","BK4581","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814414","title":"联合治疗（UTHR）雾化吸入剂Tyvaso扩大适应症申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814414","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814414?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 20:52","pubTimestamp":1788353572,"startTime":"0","endTime":"0","summary":"金吾财讯 | 联合治疗（UTHR）宣布，美国食品药品监督管理局（FDA）已正式受理其核心产品Tyvaso（曲前列尼尔，Treprostinil）雾化吸入剂的补充新药申请，用以扩大其在美国的标签范围，拓展至特发性肺纤维化（IPF）的治疗。据官方披露，FDA预计将于2027年4月下旬完成对该项申请的审查。若该申请顺利获批，雾化Tyvaso将成为全美首个且唯一用于治疗特发性肺纤维化的吸入式抗纤维化药物，极大改善患者给药体验与疗效。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1699723380.USD","LABU","UTHR","BK4532","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664153088","title":"翰宇药业(300199.SZ)：坪山分公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664153088","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664153088?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 18:52","pubTimestamp":1788346359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司坪山分公司于2026年6月18日至26日接受了美国食品药品监督管理局的现行药品生产质量管理规范常规监督检查。近日，公司收到了FDA签发的现场检查报告。此次检查是坪山分公司继2023年7-8月首次通过FDA批准前检查后，第二次接受FDA检查并顺利通过。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0070","BK0077","BK0239","BK4585","BK4588","LABU","300199","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664813240","title":"翰宇药业：坪山分公司第二次通过FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664813240","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664813240?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 18:39","pubTimestamp":1788345598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182230701","title":"医疗保健板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1182230701","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182230701?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 04:56","pubTimestamp":1788296217,"startTime":"0","endTime":"0","summary":"针对自身免疫性疾病及神经系统疾病的实验性疗法临床试验，诺华公司决定按下暂停键。此前，该试验中有三名患者不幸离世，这令投资者们心生警惕。\"与此同时，另一项关于多发性硬化症药物的独立研究传来了积极结果，受此提振，诺华股价攀升5.9%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","BK4585","LABU","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850799","title":"美股异动 | 礼来(LLY.US)涨1.69% 阿尔茨海默病血液检测获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850799","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850799?lang=zh_cn&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276923,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，礼来涨1.69%，报1176.23美元。消息面上，礼来与罗氏联合开发的Elecsys Phospho-TauPlasma血液检测已拿到美国FDA批准，用于辅助判断55岁及以上出现认知衰退症状人群，是否存在阿尔茨海默病相关脑内淀粉样蛋白病理改变。据悉，这一诊断技术直击阿尔茨海默病治疗的现实痛点。能否实现低成本、标准化、可大规模普及的筛查手段，直接决定相关药物的患者覆盖规模，也会影响新一代阿尔茨海默病药物向更早阶段人群推广的进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}